Bristol-Myers Squibb Co (MIL:1BMY) FFO


MIL:1BMY Bristol-Myers Squibb Co MIL:1BMY
49 GF Score
Price €50.56
GF Value €48.51
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Bristol-Myers Squibb Co FFO?

FFO (Funds from operations) only applies to REITs.

MIL:1BMY
49GF Score
Bristol-Myers Squibb Co MIL:1BMY
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bristol-Myers Squibb Co (MIL:1BMY) Overvalued in 2026?

Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued. The current stock price of €50.56 is trading 4.2% above its estimated GF Value™ of €48.51. GuruFocus considers Bristol-Myers Squibb Co to be Fairly Valued.

Key valuation signals for MIL:1BMY:

  • FFO:
  • GF Value™: €48.51 vs. price of €50.56 (4.2% above fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the MIL:1BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bristol-Myers Squibb Co Business Description

Address Route 206 and Province Line Road, Princeton, New Jersey, NJ, USA, 08543
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
49GF Score

Get the complete analysis for MIL:1BMY

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€50.56
Price
€48.51
GF Value